NCT00540696 - Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

June 30, 2003

Study Completion Date

September 30, 2003

Conditions

AnemiaNon-Myeloid Malignancies

Interventions

DRUG

darbepoetin alfa

"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."